Gina Klee Selected Research

Melanoma (Melanoma, Malignant)

10/2022	Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
9/2022	Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center.
10/2021	Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gina Klee Research Topics

Disease

3	Melanoma (Melanoma, Malignant) 10/2022 - 10/2021
2	Skin Neoplasms (Skin Cancer) 09/2022 - 01/2021
2	Neoplasms (Cancer) 01/2021 - 01/2021
1	Hepatitis 10/2022
1	Neoplasm Metastasis (Metastasis) 09/2022
1	Colitis 10/2021
1	Rheumatoid Arthritis 01/2021
1	COVID-19 01/2021
1	Merkel Cell Carcinoma 01/2021
1	Neointima 01/2020
1	Thrombosis (Thrombus) 01/2020
1	Extranodal NK-T-Cell Lymphoma 01/2020
1	Vascular System Injuries 01/2020

Drug/Important Bio-Agent (IBA)

3	Immune Checkpoint InhibitorsIBA 10/2022 - 01/2021
2	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2020 - 01/2020
1	Dacarbazine (DIC)FDA LinkGeneric 10/2022
1	IpilimumabIBA 10/2021
1	pembrolizumabIBA 01/2020
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2020
1	GYY 4137IBA 01/2020

Therapy/Procedure

4	Therapeutics 10/2022 - 01/2021
3	Immunotherapy 10/2022 - 10/2021
1	Drug Therapy (Chemotherapy) 10/2022
1	Radiotherapy 01/2020